Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080110 | 1.00 | GNPAT (0.51) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| SCHEMBL14625014 | 1.00 | GNPAT (0.51) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL27616755 | 0.97 | GNPAT (0.50) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| SCHEMBL3469298 | 0.82 | ECE1 (0.46) | GNPATCA2CA1 | |
| SCHEMBL3821101 | 0.82 | ECE1 (0.46) | GNPATCA2CA1 | |
| Water SCHEMBL31495128 | 0.80 | ECE1 (0.44) | GNPATCA2CA1 | |
| SCHEMBL22042308 | 0.80 | GNPAT (0.45) | GNPATTDP1SMN1; SMN2LMNAFOLH1 | |
| Hydroxyamine SCHEMBL631500 | 0.79 | CA2 (0.45) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| SCHEMBL633735 | 0.79 | CA2 (0.45) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| SCHEMBL2916092 | 0.78 | CA2 (0.48) | CA2CA4TDP1SMN1; SMN2SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136218-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-05-04 | — | — | US | claimed |
| WO-2021061874-A2 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-04-01 | — | — | WO | claimed |
| US-20200263184-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTICANCER DRUG AS ACTIVE INGREDIENTS | NATIONAL CANCER CENTER (KR) | 2020-08-20 | — | — | US | claimed |
| EP-3610866-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTICANCER DRUG AS ACTIVE INGREDIENTS | National Cancer Center (KR) | 2020-02-19 | — | — | EP | claimed |
| CN-103214451-A | Bicyclol amino acid ester and preparation method and application thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2013-07-24 | — | — | CN | claimed |
| JP-63185964-A | — | — | None | — | — | JP | disclosed |
| JP-63185950-A | — | — | None | — | — | JP | disclosed |
| JP-63185949-A | — | — | None | — | — | JP | disclosed |
| CN-120189497-A | Purified arylsulfatase A and compositions thereof | 武田药品工业株式会社 | 2025-06-24 | — | — | CN | disclosed |
| EP-4479741-A1 | METHOD FOR DETERMINING A PARAMETER OF A COMPOSITION OF NATURAL ORIGIN FOR DETERMINING THE MOST SUITABLE TREATMENT FOR THE REMOVAL OF HETEROATOMS FROM SAID COMPOSITION | TotalEnergies OneTech (FR) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024213854-A1 | METHOD FOR HYDROTREATING A COMPOSITION OF NATURAL ORIGIN | TOTALENERGIES ONETECH (FR) | 2024-10-17 | — | — | WO | disclosed |
| CN-118460505-A | Purified arylsulfatase A and compositions thereof | 武田药品工业株式会社 | 2024-08-09 | — | — | CN | disclosed |
| US-6350893-B1 | REACTION OF DIALKYL CARBONATE WITH BENZYL ALCOHOL IN THE PRESENCE OF BASIC CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2002-02-26 | — | — | US | disclosed |
| CN-1299370-A | Purification of proteins by ion exchange chromatography | GENENTECH INC (US) | 2001-06-13 | — | — | CN | disclosed |
| US-6160160-A | Process for preparing benzyl carbazates | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-12 | — | — | US | disclosed |
| EP-0987249-A1 | Process for the preparation of benzyl carbazates | Bayer Aktiengesellschaft (DE) | 2000-03-22 | — | — | EP | disclosed |
| US-5756824-A | Process for the preparation of carbazates | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-26 | — | — | US | disclosed |
| JP-S63185949-A | HYDRAZINOSUCCINIC ACID DIESTER | NISSAN CHEM IND LTD | 1988-08-01 | — | — | JP | disclosed |
| JP-S63185964-A | PRODUCTION OF PYRAZOLES | NISSAN CHEM IND LTD | 1988-08-01 | — | — | JP | disclosed |
| JP-S63185950-A | METHYLENEHYDRAZINOSUCCINIC ACID DIESTER | NISSAN CHEM IND LTD | 1988-08-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200263184-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTICANCER DRUG AS ACTIVE INGREDIENTS | SLC25A11, SLC16A1, MDH1 | GNPAT 153/4885CA2 410/4885CA4 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.